Research into treating early stage ovarian and breast cancer is due to begin at a hospital charity.
The Myrtle Peach Fund has awarded a research team at Cranfield University£15,000 for developing gynaecological services and to help patients who are at risk from, or have been treated for, cervical or ovarian cancer.
The project will focus on whether cells of the immune system can be generated in the laboratory from stem cells.
Professor Christopher B-Lynch, obstetrics and gynaecology consultant and chair of the Myrtle Peach Fund, said: 'The sooner ovarian cancer is diagnosed, the easier it is to treat. If it's caught in the early stage-one phase, up to 95% of women will live for more than five years.'
It is hoped that the results of the research will also be of help in the treatment of early stage breast cancer and ovarian cancer sufferers, as well as in reducing the risk of infection following major surgery.
The UK has one of the highest incidences of ovarian cancer in Europe, with about 6,800 women diagnosed with it in the UK each year.
Ovarian is the fifth most common women's cancer after breast, bowel, lung and womb cancer.